U.S. patent application number 13/964975 was filed with the patent office on 2014-01-02 for sublingual and buccal film compositions.
This patent application is currently assigned to RB Pharmaceuticals Limited. The applicant listed for this patent is Beuford A. Bogue, Bill J. Boone, Madhusudan Hariharan, Samuel D. Hilbert, Garry L. Myers, Pradeep Sanghvi. Invention is credited to Beuford A. Bogue, Bill J. Boone, Madhusudan Hariharan, Samuel D. Hilbert, Garry L. Myers, Pradeep Sanghvi.
Application Number | 20140005218 13/964975 |
Document ID | / |
Family ID | 43428649 |
Filed Date | 2014-01-02 |
United States Patent
Application |
20140005218 |
Kind Code |
A1 |
Myers; Garry L. ; et
al. |
January 2, 2014 |
SUBLINGUAL AND BUCCAL FILM COMPOSITIONS
Abstract
The present invention relates to products and methods for
treatment of narcotic dependence in a user. The invention more
particularly relates to self-supporting dosage forms which provide
an active agent for treating narcotic dependence while providing
sufficient buccal adhesion of the dosage form.
Inventors: |
Myers; Garry L.; (Kingsport,
TN) ; Hilbert; Samuel D.; (Jonesboro, TN) ;
Boone; Bill J.; (Johnson City, TN) ; Bogue; Beuford
A.; (Valparaiso, IN) ; Sanghvi; Pradeep;
(Dyer, IN) ; Hariharan; Madhusudan; (Munster,
IN) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Myers; Garry L.
Hilbert; Samuel D.
Boone; Bill J.
Bogue; Beuford A.
Sanghvi; Pradeep
Hariharan; Madhusudan |
Kingsport
Jonesboro
Johnson City
Valparaiso
Dyer
Munster |
TN
TN
TN
IN
IN
IN |
US
US
US
US
US
US |
|
|
Assignee: |
RB Pharmaceuticals Limited
Slough
GB
|
Family ID: |
43428649 |
Appl. No.: |
13/964975 |
Filed: |
August 12, 2013 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13923749 |
Jun 21, 2013 |
|
|
|
13964975 |
|
|
|
|
12537571 |
Aug 7, 2009 |
8475832 |
|
|
13923749 |
|
|
|
|
Current U.S.
Class: |
514/282 |
Current CPC
Class: |
A61K 9/7007 20130101;
A61K 9/006 20130101; A61K 47/26 20130101; A61K 47/22 20130101; A61K
9/0056 20130101; A61K 47/12 20130101; A61K 47/38 20130101; A61P
25/36 20180101; A61P 25/30 20180101; A61K 31/4355 20130101; A61K
31/46 20130101; A61K 47/32 20130101; A61K 31/485 20130101; A61K
47/34 20130101; A61K 47/10 20130101; A61K 31/4355 20130101; A61K
2300/00 20130101; A61K 31/485 20130101; A61K 2300/00 20130101 |
Class at
Publication: |
514/282 |
International
Class: |
A61K 9/00 20060101
A61K009/00; A61K 31/485 20060101 A61K031/485 |
Claims
1. An orally dissolving film formulation comprising from about 2 to
about 16 mg of buprenorphine and from about 0.5 to about 4 mg of
naloxone, wherein said formulation provides an in vivo plasma
profile having a mean C.sub.max of between about 0.6 ng/ml and
about 5.7 ng/ml for buprenorphine and an in vivo plasma profile
having a mean C.sub.max of between about 41 pg/ml to about 324
pg/ml for naloxone.
2. The film formulation of claim 1, comprising about 2 mg of
buprenorphine and about 0.5 mg of naloxone, wherein said
formulation provides an in vivo plasma profile having a mean
C.sub.max of between about 0.6 ng/ml and about 1.0 ng/ml for
buprenorphine and an in vivo plasma profile having a mean C.sub.max
of between about 41 pg/ml to about 65 pg/ml for naloxone.
3. The film formulation of claim 1, comprising about 4 mg of
buprenorphine and about 1 mg of naloxone, wherein said formulation
provides an in vivo plasma profile having a mean C.sub.max of
between about 1.0 ng/ml and about 1.7 ng/ml for buprenorphine and
an in vivo plasma profile having a mean C.sub.max of between about
64 pg/ml to about 102 pg/ml for naloxone.
4. The film formulation of claim 1, comprising about 8 mg of
buprenorphine and about 2 mg of naloxone, wherein said formulation
provides an in vivo plasma profile having a mean C.sub.max of
between about 1.8 ng/ml and about 2.9 ng/ml for buprenorphine and
an in vivo plasma profile having a mean C.sub.max of between about
75 pg/ml to about 119 pg/ml for naloxone.
5. The film formulation of claim 1, comprising about 12 mg of
buprenorphine and about 3 mg of naloxone, wherein said formulation
provides an in vivo plasma profile having a mean C.sub.max of
between about 2.5 ng/ml and about 4.1 ng/ml for buprenorphine and
an in vivo plasma profile having a mean C.sub.max of between about
159 pg/ml to about 250 pg/ml for naloxone.
6. The film formulation of claim 1, comprising about 16 mg of
buprenorphine and about 4 mg of naloxone, wherein said formulation
provides an in vivo plasma profile having a mean C.sub.max of
between about 3.6 ng/ml and about 5.7 ng/ml for buprenorphine and
an in vivo plasma profile having a mean C.sub.max of between about
207 pg/ml to about 324 pg/ml for naloxone.
7. An orally dissolving film formulation comprising from about 2 to
about 16 mg of buprenorphine and from about 0.5 to about 4 mg of
naloxone, wherein said formulation provides an in vivo plasma
profile having a mean C.sub.max of between about 0.7 ng/ml and
about 6.9 ng/ml for buprenorphine and an in vivo plasma profile
having a mean C.sub.max of between about 40 pg/ml to about 405
pg/ml for naloxone.
8. The film formulation of claim 7, comprising about 2 mg of
buprenorphine and about 0.5 mg of naloxone, wherein said
formulation provides an in vivo plasma profile having a mean
C.sub.max of between about 0.7 ng/ml and about 1.2 ng/ml for
buprenorphine and an in vivo plasma profile having a mean C.sub.max
of between about 40 pg/ml to about 64 pg/ml for naloxone.
9. The film formulation of claim 7, comprising about 4 mg of
buprenorphine and about 1 mg of naloxone, wherein said formulation
provides an in vivo plasma profile having a mean C.sub.max of
between about 1.2 ng/ml and about 2.0 ng/ml for buprenorphine and
an in vivo plasma profile having a mean C.sub.max of between about
72 pg/ml to about 113 pg/ml for naloxone.
10. The film formulation of claim 7, comprising about 8 mg of
buprenorphine and about 2 mg of naloxone, wherein said formulation
provides an in vivo plasma profile having a mean C.sub.max of
between about 2.1 ng/ml and about 3.4 ng/ml for buprenorphine and
an in vivo plasma profile having a mean C.sub.max of between about
104 pg/ml to about 163 pg/ml for naloxone.
11. The film formulation of claim 7, comprising about 12 mg of
buprenorphine and about 3 mg of naloxone, wherein said formulation
provides an in vivo plasma profile having a mean C.sub.max of
between about 3.3 ng/ml and about 5.3 ng/ml for buprenorphine and
an in vivo plasma profile having a mean C.sub.max of between about
196 pg/ml to about 308 pg/ml for naloxone.
12. The film formulation of claim 7, comprising about 16 mg of
buprenorphine and about 4 mg of naloxone, wherein said formulation
provides an in vivo plasma profile having a mean C.sub.max of
between about 4.3 ng/ml and about 6.9 ng/ml for buprenorphine and
an in vivo plasma profile having a mean C.sub.max of between about
259 pg/ml to about 405 pg/ml for naloxone.
13. An orally dissolving film formulation comprising buprenorphine
and naloxone that is bioequivalent to a SUBOXONE.RTM. tablet
containing from about 2 to about 16 mg of buprenorphine and from
about 0.5 to about 4 mg of naloxone such that said formulation
provides an in vivo plasma profile having a mean C.sub.max of
between about 0.6 ng/ml and about 5.7 ng/ml for buprenorphine and
an in vivo plasma profile having a mean C.sub.max of between about
41 pg/ml to about 324 pg/ml for naloxone.
14. The film formulation of claim 13 wherein said film formulation
comprising buprenorphine and naloxone is bioequivalent to a
SUBOXONE.RTM. tablet containing about 2 mg of buprenorhphine and
about 0.5 mg of naloxone such that said formulation provides an in
vivo plasma profile having a mean C.sub.max of between about 0.6
ng/ml and about 1.0 ng/ml for buprenorphine and an in vivo plasma
profile having a mean C.sub.max of between about 41 pg/ml to about
65 pg/ml for naloxone.
15. The film formulation of claim 13 wherein said film formulation
comprising buprenorphine and naloxone is bioequivalent to a
SUBOXONE.RTM. tablet containing about 4 mg of buprenorhphine and
about 1 mg of naloxone such that said formulation provides an in
vivo plasma profile having a mean C.sub.max of between about 1.0
ng/ml and about 1.7 ng/ml for buprenorphine and an in vivo plasma
profile having a mean C.sub.max of between about 64 pg/ml to about
102 pg/ml for naloxone.
16. The film formulation of claim 13 wherein said film formulation
comprising buprenorphine and naloxone is bioequivalent to a
SUBOXONE.RTM. tablet containing about 8 mg of buprenorhphine and
about 2 mg of naloxone such that said formulation provides an in
vivo plasma profile having a mean C.sub.max of between about 1.8
ng/ml and about 2.9 ng/ml for buprenorphine and an in vivo plasma
profile having a mean C.sub.max of between about 75 pg/ml to about
119 pg/ml for naloxone.
17. The film formulation of claim 13 wherein said film formulation
comprising buprenorphine and naloxone is bioequivalent to a
SUBOXONE.RTM. tablet containing about 12 mg of buprenorhphine and
about 3 mg of naloxone such that said formulation provides an in
vivo plasma profile having a mean C.sub.max of between about 2.5
ng/ml and about 4.1 ng/ml for buprenorphine and an in vivo plasma
profile having a mean C.sub.max of between about 159 pg/ml to about
250 pg/ml for naloxone.
18. The film formulation of claim 13 wherein said film formulation
comprising buprenorphine and naloxone is bioequivalent to a
SUBOXONE.RTM. tablet containing about 16 mg of buprenorhphine and
about 4 mg of naloxone such that said formulation provides an in
vivo plasma profile having a mean C.sub.max of between about 3.6
ng/ml and about 5.7 ng/ml for buprenorphine and an in vivo plasma
profile having a mean C.sub.max of between about 207 pg/ml to about
324 pg/ml for naloxone.
19. An orally dissolving film formulation comprising buprenorphine
and naloxone that is bioequivalent to a SUBOXONE.RTM. Film
comprising from about 2 to about 16 mg of buprenorphine and from
about 0.5 to about 4 mg of naloxone such that said formulation
provides an in vivo plasma profile having a mean C.sub.max of
between about 0.7 ng/ml and about 6.9 ng/ml for buprenorphine and
an in vivo plasma profile having a mean C.sub.max of between about
40 pg/ml to about 405 pg/ml for naloxone.
20. The film formulation of claim 19 wherein said film formulation
comprising buprenorphine and naloxone is bioequivalent to a
SUBOXONE.RTM. Film comprising about 2 mg of buprenorphine and about
0.5 mg of naloxone such that said formulation provides an in vivo
plasma profile having a mean C.sub.max of between about 0.6 ng/ml
and about 1.0 ng/ml for buprenorphine and an in vivo plasma profile
having a mean C.sub.max of between about 41 pg/ml to about 65 pg/ml
for naloxone.
21. The film formulation of claim 19 wherein said film formulation
comprising buprenorphine and naloxone is bioequivalent to a
SUBOXONE.RTM. Film comprising about 4 mg of buprenorphine and about
1 mg of naloxone such that said formulation provides an in vivo
plasma profile having a mean C.sub.max of between about 1.2 ng/ml
and about 2.0 ng/ml for buprenorphine and an in vivo plasma profile
having a mean C.sub.max of between about 72 pg/ml to about 113
pg/ml for naloxone.
22. The film formulation of claim 19 wherein said film formulation
comprising buprenorphine and naloxone is bioequivalent to a
SUBOXONE.RTM. Film comprising about 8 mg of buprenorphine and about
2 mg of naloxone such that said formulation provides an in vivo
plasma profile having a mean C.sub.max of between about 2.1 ng/ml
and about 3.4 ng/ml for buprenorphine and an in vivo plasma profile
having a mean C.sub.max of between about 104 pg/ml to about 163
pg/ml for naloxone.
23. The film formulation of claim 19 wherein said film formulation
comprising buprenorphine and naloxone is bioequivalent to a
SUBOXONE.RTM. Film comprising about 12 mg of buprenorphine and
about 3 mg of naloxone such that said formulation provides an in
vivo plasma profile having a mean C.sub.max of between about 3.3
ng/ml and about 5.3 ng/ml for buprenorphine and an in vivo plasma
profile having a mean C.sub.max of between about 196 pg/ml to about
308 pg/ml for naloxone.
24. The film formulation of claim 19 wherein said film formulation
comprising buprenorphine and naloxone is bioequivalent to a
SUBOXONE.RTM. Film comprising about 16 mg of buprenorphine and
about 4 mg of naloxone such that said formulation provides an in
vivo plasma profile having a mean C.sub.max of between about 4.3
ng/ml and about 6.9 ng/ml for buprenorphine and an in vivo plasma
profile having a mean C.sub.max of between about 259 pg/ml to about
405.00 pg/ml for naloxone.
Description
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application is a continuation of U.S. application Ser.
No. 13/923,749, filed Jun. 21, 2013, which is a continuation of
U.S. application Ser. No. 12/537,571 filed Aug. 7, 2009, now U.S.
Pat. No. 8,475,832, issued Jul. 2, 2013.
FIELD OF THE INVENTION
[0002] The present invention relates to compositions, methods of
manufacture, products and methods of use relating to films
containing therapeutic actives. The invention more particularly
relates to self-supporting film dosage forms which provide a
therapeutically effective dosage, essentially matching that of
currently-marketed tablets containing the same active. Such
compositions are particularly useful for treating narcotic
dependence while providing sufficient buccal adhesion of the dosage
form.
BACKGROUND OF THE RELATED TECHNOLOGY
[0003] Oral administration of two therapeutic actives in a single
dosage form can be complex if the intention is to have one active
absorbed into the body and the other active remain substantially
unabsorbed. For example, one active may be relatively soluble in
the mouth at one pH, and the other active may be relatively
insoluble at the same pH. Moreover, the absorption kinetics of each
therapeutic agent may be substantially different due to differing
absorption of the charged and uncharged species. These factors
represent some of the challenges in appropriately co-administering
therapeutic agents.
[0004] Co-administration of therapeutic agents has many
applications. Among such areas of treatment include treating
individuals who suffer from narcotic dependence. Such individuals
have a tendency to suffer from serious physical dependence on the
narcotic, resulting in potentially dangerous withdrawal effects
when the narcotic is not administered to the individual. In order
to help individuals addicted to narcotics, it is known to provide a
reduced level of a drug, which provides an effect of satisfying the
body's urge for the narcotic, but does not provide the "high" that
is provided by the misuse of the narcotic. The drug provided may be
an agonist or a partial agonist, which provides a reduced sensation
and may help lower dependence on the drug. However, even though
these drugs provide only a low level of euphoric effect, they are
capable of being abused by the individuals parenterally. In such
cases, it is desirable to provide a combination of the drug with a
second drug, which may decrease the likelihood of diversion and
abuse of the first drug. For example, it is known to provide a
dosage of an antagonist in combination with the agonist or partial
agonist. The narcotic antagonist binds to a receptor in the brain
to block the receptor, thus reducing the effect of the agonist.
[0005] One such combination of drugs has been marketed under the
trade name Suboxone.RTM. as an orally ingestible tablet. However,
such combinations in tablet form have the potential for abuse. In
some instances, the patient who has been provided the drug may
store the tablet in his mouth without swallowing the tablet, then
later extract the agonist from the tablet and inject the drug into
an individual's body. Although certain antagonists (such as highly
water-soluble antagonists) may be used to help reduce the ability
to separate the agonist, the potential for abuse still exists. It
is desired to provide a dosage that cannot be easily removed from
the mouth once it has been administered.
[0006] There is currently a need for an orally dissolvable film
dosage form that provides the desired absorption levels of the
agonist and antagonist, while providing an adhesive effect in the
mouth, rendering it difficult to remove once placed in the mouth,
thereby making abuse of the agonist difficult.
SUMMARY OF THE INVENTION
[0007] In one embodiment of the present invention, there is
provided a film dosage composition including: a polymeric carrier
matrix; a therapeutically effective amount of buprenorphine or a
pharmaceutically acceptable salt thereof; a therapeutically
effective amount of naloxone or a pharmaceutically acceptable salt
thereof; and a buffer in an amount to provide a pH of the
composition of a value sufficient to optimize absorption of the
buprenorphine.
[0008] In another embodiment of the present invention, there is
provided a film dosage composition including: a polymeric carrier
matrix; a therapeutically effective amount of buprenorphine or a
pharmaceutically acceptable salt thereof; a therapeutically
effective amount of naloxone or a pharmaceutically acceptable salt
thereof; and a buffer in an amount sufficient to inhibit the
absorption of the naloxone when administered orally.
[0009] In still other embodiments, there may be provided a film
dosage composition including: a polymeric carrier matrix; a
therapeutically effective amount of buprenorphine or a
pharmaceutically acceptable salt thereof; a therapeutically
effective amount of naloxone or a pharmaceutically acceptable salt
thereof; and a buffering system; where the buffering system
includes a buffer capacity sufficient to maintain the ionization of
naloxone during the time which the composition is in the oral
cavity of a user.
[0010] In another embodiment of the invention, there is provided a
method of treating narcotic dependence of a user, including the
steps of: providing a composition including: a polymeric carrier
matrix; a therapeutically effective amount of buprenorphine or a
pharmaceutically acceptable salt thereof; a therapeutically
effective amount of naloxone or a pharmaceutically acceptable salt
thereof; and a buffer in an amount to provide a pH of the
composition of a value sufficient to optimize absorption of the
buprenorphine; and administering the composition to the oral cavity
of a user.
[0011] In still another embodiment of the invention, there is
provided a process of forming a film dosage composition including
the steps of: casting a film-forming composition, the film-forming
composition including: a polymeric carrier matrix; a
therapeutically effective amount of buprenorphine or a
pharmaceutically acceptable salt thereof; a therapeutically
effective amount of naloxone or a pharmaceutically acceptable salt
thereof; and a buffer in an amount to provide a pH of the
composition of a value sufficient to optimize absorption of the
buprenorphine and drying the film-forming composition to form a
self-supporting film dosage composition.
[0012] In another embodiment, there is provided a film dosage
composition including a therapeutically sufficient amount of
buprenorphine or a pharmaceutically acceptable salt thereof and a
therapeutically sufficient amount of naloxone or a pharmaceutically
acceptable salt thereof, the film dosage composition having a
bioequivalent release profile as compared to a Suboxone.RTM. tablet
containing about 2 times the amount of buprenorphine or a
pharmaceutically acceptable salt thereof.
[0013] Still other embodiments of the present invention provide an
orally dissolving film formulation including buprenorphine and
naloxone, where the formulation provides an in-vivo plasma profile
having a Cmax of between about 0.624 ng/ml and about 5.638 ng/ml
for buprenorphine and an in-vivo plasma profile having a Cmax of
between about 41.04 pg/ml to about 323.75 pg/ml for naloxone.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Definitions
[0014] As used herein, the term Cmax refers to the mean maximum
plasma concentration after administration of the composition to a
human subject. As also used herein, the term AUC refers to the mean
area under the plasma concentration-time curve value after
administration of the compositions formed herein. As will be set
forth in more detail below, the term "optimizing the absorption"
does not refer to reaching the maximum absorption of the
composition, and rather refers to reaching the optimum level of
absorption at a pH of about 2 to about 4. The "optimum" absorption
may be, for example, a level that provides a bioequivalent
absorption as administration of the currently available
Suboxone.RTM. tablet. An "optimum" Cmax of buprenorphine is about
0.67 to about 5.36 mg/ml at dosages of from 2-16 mg buprenorphine
at a given pH. Similarly, an "optimum" AUC of buprenorphine may be
about 7.43 to about 59.46 hr*ng/ml at dosages of from 2-16 mg
buprenorphine at a given pH. As will be described in more detail
below, it has been surprisingly discovered that the absorption of
one particular agonist, buprenorphine, can provide an optimum
absorption at a pH of about 2-4 as well as about 5.5-6.5. Thus, one
may "optimize" the absorption of buprenorphine by providing a pH of
about 2-4 or about 5.5-6.5.
[0015] "Maximizing the absorption" refers to the maximum in vivo
absorption values achieved at a pH of about 4 to about 9.
[0016] The term "local pH" refers to the pH of the region of the
carrier matrix immediately surrounding the active agent as the
matrix hydrates and/or dissolves, for example, in the mouth of the
user.
[0017] By "inhibiting" the absorption of an active, it is meant
achieving as complete an ionization state of the active as
possible, such that little to none of the active is measurably
absorbable. For example, at a pH of 3-3.5, the Cmax of an active
such as naloxone for dosage of 0.5 mg to 4.0 mg ranges from 32.5 to
260 pg/ml, and an AUC of naloxone for dosage of 0.5 mg to 4.0 mg
ranges from 90.55 to 724.4 hr*pg/ml. It is understood that at a pH
lower than 3.0, further ionization would be expected and thus
result in lower absorption.
[0018] The term "bioequivalent" means obtaining 80% to 125% of the
Cmax and AUC values for a given active in a different product. For
example, assuming Cmax and AUC values of buprenorphine for a
commercially-available Suboxone.RTM. tablet (containing 2 mg
buprenorphine and 0.5 mg naloxone) are 0.780 ng/ml and 6.789
hr*ng/ml, respectively, a bioequivalent product would have a Cmax
of buprenorphine in the range of 0.624-0.975 ng/ml, and an AUC
value of buprenorphine of 5.431-8.486 hr*ng/ml.
[0019] It will be understood that the term "film" includes thin
films and sheets, in any shape, including rectangular, square, or
other desired shape. The films described herein may be any desired
thickness and size such that it may be placed into the oral cavity
of the user. For example, the films may have a relatively thin
thickness of from about 0.1 to about 10 mils, or they may have a
somewhat thicker thickness of from about 10 to about 30 mils. For
some films, the thickness may be even larger, i.e., greater than
about 30 mils. Films may be in a single layer or they may be
multi-layered, including laminated films.
[0020] Oral dissolving films generally fall into three main
classes: fast dissolving, moderate dissolving and slow dissolving.
Fast dissolving films generally dissolve in about 1 second to about
30 seconds in the mouth. Moderate dissolving films generally
dissolve in about 1 to about 30 minutes in the mouth, and slow
dissolving films generally dissolve in more than 30 minutes in the
mouth. Fast dissolving films may consist of low molecular weight
hydrophilic polymers (i.e., polymers having a molecular weight
between about 1,000 to 9,000, or polymers having a molecular weight
up to 200,000). In contrast, slow dissolving films generally have
high molecular weight polymers (i.e., having a molecular weight in
the millions).
[0021] Moderate dissolving films tend to fall in between the fast
and slow dissolving films. Moderate dissolving films dissolve
rather quickly, but also have a good level of mucoadhesion.
Moderate dissolving films are also flexible, quickly wettable, and
are typically non-irritating to the user. For the instant
invention, it is preferable to use films that fall between the
categories of fast dissolving and moderate dissolving. Such
moderate dissolving films provide a quick enough dissolution rate,
most desirably between about 1 minute and about 20 minutes, while
providing an acceptable mucoadhesion level such that the film is
not easily removable once it is placed in the oral cavity of the
user.
[0022] Inventive films described herein may include one or more
agonists or partial agonists used for the treatment of drug
addiction. As used herein, the term "agonist" refers to a chemical
substance that is capable of providing a physiological response or
activity in the body of the user. The films described herein may
further include one or more antagonists. As used herein, the term
"antagonist" refers to any chemical substance that acts within the
body of the user to reduce the physiological activity of another
chemical substance. In some embodiments, an antagonist used herein
may act to reduce and/or block the physiological activity of the
agonist. The actives may be water-soluble, or they may be
water-insoluble. As used herein, the term "water-soluble" refers to
substances that are at least partially dissolvable in a solvent,
including but not limited to water. The term "water-soluble" does
not necessarily mean that the substance is 100% dissolvable in the
solvent. The term "water-insoluble" refers to substances that are
not dissolvable in a solvent, including but not limited to water.
Solvents may include water, or alternatively may include other
polar solvents by themselves or in combination with water.
Inventive Films
[0023] The present invention relates to methods of treating
narcotic dependence in an individual. More desirably, the invention
relates to the treatment of opioid dependence in an individual,
while using a formulation and delivery that hinders misuse of the
narcotic. Currently, treatment of opioid dependence is aided by
administration of Suboxone.RTM., which is an orally dissolvable
tablet. This tablet which provides a combination of buprenorphine
(an opioid agonist) and naloxone (an opioid antagonist). Therefore,
the present invention provides a method of treating narcotic
dependence by providing an orally dissolvable film dosage, which
provides a bioequivalent effect to Suboxone.RTM.. The film dosage
preferably provides buccal adhesion while it is in the user's
mouth, rendering it difficult to remove after placement.
[0024] The film dosage composition preferably includes a polymeric
carrier matrix. Any desired polymeric carrier matrix may be used,
provided that it is orally dissolvable. Desirably, the dosage
should have enough bioadhesion to not be easily removed and it
should form a gel like structure when administered. The orally
consumable films are preferably moderate-dissolving in the oral
cavity and particularly suitable for delivery of actives, although
both fast and sustained release compositions are also among the
various embodiments contemplated.
[0025] The films used in the pharmaceutical products may be
produced by a combination of at least one polymer and a solvent,
optionally including other fillers known in the art. The solvent
may be water, a polar organic solvent including, but not limited
to, ethanol, isopropanol, acetone, or any combination thereof. In
some embodiments, the solvent may be a non-polar organic solvent,
such as methylene chloride. The film may be prepared by utilizing a
selected casting or deposition method and a controlled drying
process. For example, the film may be prepared through controlled
drying processes, which include application of heat and/or
radiation energy to the wet film matrix to form a visco-elastic
structure, thereby controlling the uniformity of content of the
film. Such processes are described in more detail in commonly
assigned U.S. application Ser. No. 10/074,272, filed on Feb. 14,
2002, and published as U.S. Patent Publication No. 2003/0107149 A1,
the contents of which are incorporated herein by reference in their
entirety. Alternatively, the films may be extruded as described in
commonly assigned U.S. application Ser. No. 10/856,176, filed on
May 28, 2004, and published as U.S. Patent Publication No.
2005/0037055 A1, the contents of which are incorporated herein by
reference in their entirety.
[0026] The polymer included in the films may be water-soluble,
water-swellable, water-insoluble, or a combination of one or more
either water-soluble, water-swellable or water-insoluble polymers.
The polymer may include cellulose or a cellulose derivative.
Specific examples of useful water-soluble polymers include, but are
not limited to, polyethylene oxide, pullulan, hydroxypropylmethyl
cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose,
polyvinyl pyrrolidone, carboxymethyl cellulose, polyvinyl alcohol,
sodium alginate, polyethylene glycol, xanthan gum, tragancanth gum,
guar gum, acacia gum, arabic gum, polyacrylic acid,
methylmethacrylate copolymer, carboxyvinyl copolymers, starch,
gelatin, and combinations thereof. Specific examples of useful
water-insoluble polymers include, but are not limited to, ethyl
cellulose, hydroxypropyl ethyl cellulose, cellulose acetate
phthalate, hydroxypropyl methyl cellulose phthalate and
combinations thereof. For higher dosages, it may be desirable to
incorporate a polymer that provides a high level of viscosity as
compared to lower dosages.
[0027] As used herein the phrase "water-soluble polymer" and
variants thereof refer to a polymer that is at least partially
soluble in water, and desirably fully or predominantly soluble in
water, or absorbs water. Polymers that absorb water are often
referred to as being water-swellable polymers. The materials useful
with the present invention may be water-soluble or water-swellable
at room temperature and other temperatures, such as temperatures
exceeding room temperature. Moreover, the materials may be
water-soluble or water-swellable at pressures less than atmospheric
pressure. Desirably, the water-soluble polymers are water-soluble
or water-swellable having at least 20 percent by weight water
uptake. Water-swellable polymers having a 25 or greater percent by
weight water uptake are also useful. In some embodiments, films
formed from such water-soluble polymers may be sufficiently
water-soluble to be dissolvable upon contact with bodily
fluids.
[0028] Other polymers useful for incorporation into the films
include biodegradable polymers, copolymers, block polymers and
combinations thereof. It is understood that the term
"biodegradable" is intended to include materials that chemically
degrade, as opposed to materials that physically break apart (i.e.,
bioerodable materials). Among the known useful polymers or polymer
classes which meet the above criteria are: poly(glycolic acid)
(PGA), poly(lactic acid) (PLA), polydioxanes, polyoxalates,
poly(.alpha.-esters), polyanhydrides, polyacetates,
polycaprolactones, poly(orthoesters), polyamino acids,
polyaminocarbonates, polyurethanes, polycarbonates, polyamides,
poly(alkyl cyanoacrylates), and mixtures and copolymers thereof.
Additional useful polymers include, stereopolymers of L- and
D-lactic acid, copolymers of bis(p-carboxyphenoxy) propane acid and
sebacic acid, sebacic acid copolymers, copolymers of caprolactone,
poly(lactic acid)/poly(glycolic acid)/polyethyleneglycol
copolymers, copolymers of polyurethane and (poly(lactic acid),
copolymers of polyurethane and poly(lactic acid), copolymers of
.alpha.-amino acids, copolymers of .alpha.-amino acids and caproic
acid, copolymers of .alpha.-benzyl glutamate and polyethylene
glycol, copolymers of succinate and poly(glycols), polyphosphazene,
polyhydroxy-alkanoates and mixtures thereof. Binary and ternary
systems are contemplated.
[0029] Other specific polymers useful include those marketed under
the Medisorb and Biodel trademarks. The Medisorb materials are
marketed by the Dupont Company of Wilmington, Del. and are
generically identified as a "lactide/glycolide co-polymer"
containing "propanoic acid, 2-hydroxy-polymer with hydroxy-polymer
with hydroxyacetic acid." Four such polymers include
lactide/glycolide 100 L, believed to be 100% lactide having a
melting point within the range of 338.degree.-347.degree. F.
(170.degree.-175.degree. C.); lactide/glycolide 100 L, believed to
be 100% glycolide having a melting point within the range of
437.degree.-455.degree. F. (225.degree.-235.degree. C.);
lactide/glycolide 85/15, believed to be 85% lactide and 15%
glycolide with a melting point within the range of
338.degree.-347.degree. F. (170.degree.-175.degree. C.); and
lactide/glycolide 50/50, believed to be a copolymer of 50% lactide
and 50% glycolide with a melting point within the range of
338.degree.-347.degree. F. (170.degree.-175.degree. C.).
[0030] The Biodel materials represent a family of various
polyanhydrides which differ chemically.
[0031] Although a variety of different polymers may be used, it is
desired to select polymers that provide mucoadhesive properties to
the film, as well as a desired dissolution and/or disintegration
rate. In particular, the time period for which it is desired to
maintain the film in contact with the mucosal tissue depends on the
type of active contained in the composition. Some actives may only
require a few minutes for delivery through the mucosal tissue,
whereas other actives may require up to several hours or even
longer. Accordingly, in some embodiments, one or more water-soluble
polymers, as described above, may be used to form the film. In
other embodiments, however, it may be desirable to use combinations
of water-soluble polymers and polymers that are water-swellable,
water-insoluble and/or biodegradable, as provided above. The
inclusion of one or more polymers that are water-swellable,
water-insoluble and/or biodegradable may provide films with slower
dissolution or disintegration rates than films formed from
water-soluble polymers alone. As such, the film may adhere to the
mucosal tissue for longer periods or time, such as up to several
hours, which may be desirable for delivery of certain active
components.
[0032] Desirably, the individual film dosage has a small size,
which is between about 0.5-1 inch by about 0.5-1 inch. Most
preferably, the film dosage is about 0.75 inches.times.0.5 inches.
The film dosage should have good adhesion when placed in the buccal
cavity or in the sublingual region of the user. Further, the film
dosage should disperse and dissolve at a moderate rate, most
desirably dispersing within about 1 minute and dissolving within
about 3 minutes. In some embodiments the film dosage may be capable
of dispersing and dissolving at a rate of between about 1 to about
1.5 minutes.
[0033] For instance, in some embodiments, the films may include
polyethylene oxide alone or in combination with a second polymer
component. The second polymer may be another water-soluble polymer,
a water-swellable polymer, a water-insoluble polymer, a
biodegradable polymer or any combination thereof. Suitable
water-soluble polymers include, without limitation, any of those
provided above. In some embodiments, the water-soluble polymer may
include hydrophilic cellulosic polymers, such as hydroxypropyl
cellulose and/or hydroxypropylmethyl cellulose. In accordance with
some embodiments, polyethylene oxide may range from about 20% to
100% by weight in the polymer component, more specifically about
30% to about 70% by weight, and even more specifically about 40% to
about 60% by weight. In some embodiments, one or more
water-swellable, water-insoluble and/or biodegradable polymers also
may be included in the polyethylene oxide-based film. Any of the
water-swellable, water-insoluble or biodegradable polymers provided
above may be employed. The second polymer component may be employed
in amounts of about 0% to about 80% by weight in the polymer
component, more specifically about 30% to about 70% by weight, and
even more specifically about 40% to about 60% by weight.
[0034] The molecular weight of the polyethylene oxide also may be
varied. In some embodiments, high molecular weight polyethylene
oxide, such as about 4 million, may be desired to increase
mucoadhesivity of the film. In some other embodiments, the
molecular weight may range from about 100,000 to 900,000, more
specifically from about 100,000 to 600,000, and even more
specifically from about 100,000 to 300,000. In some embodiments, it
may be desirable to combine high molecular weight (600,000 to
900,000) with low molecular weight (100,000 to 300,000)
polyethylene oxide in the polymer component.
[0035] A variety of optional components and fillers also may be
added to the films. These may include, without limitation:
surfactants; plasticizers; polyalcohols; anti-foaming agents, such
as silicone-containing compounds, which promote a smoother film
surface by releasing oxygen from the film; thermo-setting gels such
as pectin, carageenan, and gelatin, which help in maintaining the
dispersion of components; inclusion compounds, such as
cyclodextrins and caged molecules; coloring agents; and flavors. In
some embodiments, more than one active components may be included
in the film.
[0036] Additives may be included in the films. Examples of classes
of additives include excipients, lubricants, buffering agents,
stabilizers, blowing agents, pigments, coloring agents, fillers,
bulking agents, sweetening agents, flavoring agents, fragrances,
release modifiers, adjuvants, plasticizers, flow accelerators, mold
release agents, polyols, granulating agents, diluents, binders,
buffers, absorbents, glidants, adhesives, anti-adherents,
acidulants, softeners, resins, demulcents, solvents, surfactants,
emulsifiers, elastomers and mixtures thereof. These additives may
be added with the active ingredient(s).
[0037] Useful additives include, for example, gelatin, vegetable
proteins such as sunflower protein, soybean proteins, cotton seed
proteins, peanut proteins, grape seed proteins, whey proteins, whey
protein isolates, blood proteins, egg proteins, acrylated proteins,
water-soluble polysaccharides such as alginates, carrageenans, guar
gum, agar-agar, xanthan gum, gellan gum, gum arabic and related
gums (gum ghatti, gum karaya, gum tragancanth), pectin,
water-soluble derivatives of cellulose: alkylcelluloses
hydroxyalkylcelluloses and hydroxyalkylalkylcelluloses, such as
methylcelulose, hydroxymethylcellulose, hydroxyethylcellulose,
hydroxypropylcellulose, hydroxyethylmethylcellulose,
hydroxypropylmethylcellulose, hydroxybutylmethylcellulose,
cellulose esters and hydroxyalkylcellulose esters such as cellulose
acetate phthalate (CAP), hydroxypropylmethylcellulose (HPMC);
carboxyalkylcelluloses, carboxyalkylalkylcelluloses,
carboxyalkylcellulose esters such as carboxymethylcellulose and
their alkali metal salts; water-soluble synthetic polymers such as
polyacrylic acids and polyacrylic acid esters, polymethacrylic
acids and polymethacrylic acid esters, polyvinylacetates,
polyvinylalcohols, polyvinylacetatephthalates (PVAP),
polyvinylpyrrolidone (PVP), PVY/vinyl acetate copolymer, and
polycrotonic acids; also suitable are phthalated gelatin, gelatin
succinate, crosslinked gelatin, shellac, water-soluble chemical
derivatives of starch, cationically modified acrylates and
methacrylates possessing, for example, a tertiary or quaternary
amino group, such as the diethylaminoethyl group, which may be
quaternized if desired; and other similar polymers.
[0038] Such extenders may optionally be added in any desired amount
desirably within the range of up to about 80%, desirably about 3%
to 50% and more desirably within the range of 3% to 20% based on
the weight of all film components.
[0039] Further additives may flow agents and opacifiers, such as
the oxides of magnesium aluminum, silicon, titanium, etc. desirably
in a concentration range of about 0.02% to about 3% by weight and
desirably about 0.02% to about 1% based on the weight of all film
components.
[0040] Further examples of additives are plasticizers which include
polyalkylene oxides, such as polyethylene glycols, polypropylene
glycols, polyethylene-propylene glycols, organic plasticizers with
low molecular weights, such as glycerol, glycerol monoacetate,
diacetate or triacetate, triacetin, polysorbate, cetyl alcohol,
propylene glycol, sorbitol, sodium diethylsulfosuccinate, triethyl
citrate, tributyl citrate, and the like, added in concentrations
ranging from about 0.5% to about 30%, and desirably ranging from
about 0.5% to about 20% based on the weight of the polymer.
[0041] There may further be added compounds to improve the texture
properties of the starch material such as animal or vegetable fats,
desirably in their hydrogenated form, especially those which are
solid at room temperature. These fats desirably have a melting
point of 50.degree. C. or higher. Preferred are tri-glycerides with
C.sub.12-, C.sub.14-, C.sub.16-, C.sub.18-, C.sub.20- and
C.sub.22-fatty acids. These fats can be added alone without adding
extenders or plasticizers and can be advantageously added alone or
together with mono- and/or di-glycerides or phosphatides,
especially lecithin. The mono- and di-glycerides are desirably
derived from the types of fats described above, i.e. with
C.sub.12-, C.sub.14-, C.sub.16-, C.sub.18-, C.sub.20- and
C.sub.22-fatty acids.
[0042] The total amounts used of the fats, mono-, di-glycerides
and/or lecithins are up to about 5% and preferably within the range
of about 0.5% to about 2% by weight of the total film
composition.
[0043] It further may be useful to add silicon dioxide, calcium
silicate, or titanium dioxide in a concentration of about 0.02% to
about 1% by weight of the total composition. These compounds act as
flow agents and opacifiers.
[0044] Lecithin is one surface active agent for use in the films
described herein. Lecithin may be included in the feedstock in an
amount of from about 0.25% to about 2.00% by weight. Other surface
active agents, i.e. surfactants, include, but are not limited to,
cetyl alcohol, sodium lauryl sulfate, the Spans.TM. and Tweens.TM.
which are commercially available from ICI Americas, Inc.
Ethoxylated oils, including ethoxylated castor oils, such as
Cremophor.RTM. EL which is commercially available from BASF, are
also useful. Carbowax.TM. is yet another modifier which is very
useful in the present invention. Tweens.TM. or combinations of
surface active agents may be used to achieve the desired
hydrophilic-lipophilic balance ("HLB"). The present invention,
however, does not require the use of a surfactant and films or
film-forming compositions of the present invention may be
essentially free of a surfactant while still providing the
desirable uniformity features of the present invention.
[0045] Other ingredients include binders which contribute to the
ease of formation and general quality of the films. Non-limiting
examples of binders include starches, pregelatinize starches,
gelatin, polyvinylpyrrolidone, methylcellulose, sodium
carboxymethylcellulose, ethylcellulose, polyacrylamides,
polyvinyloxoazolidone, and polyvinylalcohols.
[0046] Further potential additives include solubility enhancing
agents, such as substances that form inclusion compounds with
active components. Such agents may be useful in improving the
properties of very insoluble and/or unstable actives. In general,
these substances are doughnut-shaped molecules with hydrophobic
internal cavities and hydrophilic exteriors. Insoluble and/or
instable actives may fit within the hydrophobic cavity, thereby
producing an inclusion complex, which is soluble in water.
Accordingly, the formation of the inclusion complex permits very
insoluble and/or instable actives to be dissolved in water. A
particularly desirable example of such agents are cyclodextrins,
which are cyclic carbohydrates derived from starch. Other similar
substances, however, are considered well within the scope of the
present invention.
[0047] Suitable coloring agents include food, drug and cosmetic
colors (FD&C), drug and cosmetic colors (D&C), or external
drug and cosmetic colors (Ext. D&C). These colors are dyes,
their corresponding lakes, and certain natural and derived
colorants. Lakes are dyes absorbed on aluminum hydroxide.
[0048] Other examples of coloring agents include known azo dyes,
organic or inorganic pigments, or coloring agents of natural
origin. Inorganic pigments are preferred, such as the oxides or
iron or titanium, these oxides, being added in concentrations
ranging from about 0.001 to about 10%, and preferably about 0.5 to
about 3%, based on the weight of all the components.
[0049] Flavors may be chosen from natural and synthetic flavoring
liquids. An illustrative list of such agents includes volatile
oils, synthetic flavor oils, flavoring aromatics, oils, liquids,
oleoresins or extracts derived from plants, leaves, flowers,
fruits, stems and combinations thereof. A non-limiting
representative list of examples includes mint oils, cocoa, and
citrus oils such as lemon, orange, grape, lime and grapefruit and
fruit essences including apple, pear, peach, grape, strawberry,
raspberry, cherry, plum, pineapple, apricot or other fruit
flavors.
[0050] Other useful flavorings include aldehydes and esters such as
benzaldehyde (cherry, almond), citral i.e., alphacitral (lemon,
lime), neral, i.e., beta-citral (lemon, lime), decanal (orange,
lemon), aldehyde C-8 (citrus fruits), aldehyde C-9 (citrus fruits),
aldehyde C-12 (citrus fruits), tolyl aldehyde (cherry, almond),
2,6-dimethyloctanol (green fruit), and 2-dodecenal (citrus,
mandarin), combinations thereof and the like.
[0051] The sweeteners may be chosen from the following non-limiting
list: glucose (corn syrup), dextrose, invert sugar, fructose, and
combinations thereof; saccharin and its various salts such as the
sodium salt; dipeptide sweeteners such as aspartame;
dihydrochalcone compounds, glycyrrhizin; Stevia Rebaudiana
(Stevioside); chloro derivatives of sucrose such as sucralose;
sugar alcohols such as sorbitol, mannitol, xylitol, and the like.
Also contemplated are hydrogenated starch hydrolysates and the
synthetic sweetener
3,6-dihydro-6-methyl-1-1-1,2,3-oxathiazin-4-one-2,2-dioxide,
particularly the potassium salt (acesulfame-K), and sodium and
calcium salts thereof, and natural intensive sweeteners, such as Lo
Han Kuo. Other sweeteners may also be used.
[0052] Anti-foaming and/or de-foaming components may also be used
with the films. These components aid in the removal of air, such as
entrapped air, from the film-forming compositions. Such entrapped
air may lead to non-uniform films. Simethicone is one particularly
useful anti-foaming and/or de-foaming agent. The present invention,
however, is not so limited and other anti-foam and/or de-foaming
agents may suitable be used.
[0053] As a related matter, simethicone and related agents may be
employed for densification purposes. More specifically, such agents
may facilitate the removal of voids, air, moisture, and similar
undesired components, thereby providing denser, and thus more
uniform films. Agents or components which perform this function can
be referred to as densification or densifying agents. As described
above, entrapped air or undesired components may lead to
non-uniform films.
[0054] Simethicone is generally used in the medical field as a
treatment for gas or colic in babies. Simethicone is a mixture of
fully methylated linear siloxane polymers containing repeating
units of polydimethylsiloxane which is stabilized with
trimethylsiloxy end-blocking unites, and silicon dioxide. It
usually contains 90.5-99% polymethylsiloxane and 4-7% silicon
dioxide. The mixture is a gray, translucent, viscous fluid which is
insoluble in water.
[0055] When dispersed in water, simethicone will spread across the
surface, forming a thin film of low surface tension. In this way,
simethicone reduces the surface tension of bubbles air located in
the solution, such as foam bubbles, causing their collapse. The
function of simethicone mimics the dual action of oil and alcohol
in water. For example, in an oily solution any trapped air bubbles
will ascend to the surface and dissipate more quickly and easily,
because an oily liquid has a lighter density compared to a water
solution. On the other hand, an alcohol/water mixture is known to
lower water density as well as lower the water's surface tension.
So, any air bubbles trapped inside this mixture solution will also
be easily dissipated. Simethicone solution provides both of these
advantages. It lowers the surface energy of any air bubbles that
trapped inside the aqueous solution, as well as lowering the
surface tension of the aqueous solution. As the result of this
unique functionality, simethicone has an excellent anti-foaming
property that can be used for physiological processes (anti-gas in
stomach) as well as any for external processes that require the
removal of air bubbles from a product.
[0056] In order to prevent the formation of air bubbles in the
films, the mixing step can be performed under vacuum. However, as
soon as the mixing step is completed, and the film solution is
returned to the normal atmosphere condition, air will be
re-introduced into or contacted with the mixture. In many cases,
tiny air bubbles will be again trapped inside this polymeric
viscous solution. The incorporation of simethicone into the
film-forming composition either substantially reduces or eliminates
the formation of air bubbles.
[0057] Simethicone may be added to the film-forming mixture as an
anti-foaming agent in an amount from about 0.01 weight percent to
about 5.0 weight percent, more desirably from about 0.05 weight
percent to about 2.5 weight percent, and most desirably from about
0.1 weight percent to about 1.0 weight percent.
[0058] Any other optional components described in commonly assigned
U.S. Pat. No. 7,425,292 and U.S. application Ser. No. 10/856,176,
referred to above, also may be included in the films described
herein.
[0059] When the dosage form includes at least one antagonist, it
may be desired to control the release of the antagonist, so as to
delay or wholly prevent the release of the antagonist from the
dosage when taken orally. Desirably, the dosage form is a
self-supporting film composition, which is placed into the oral
cavity of the user. In a dosage form that is to be placed in the
oral cavity, it is desired to absorb the agonist buccally, so as to
provide rapid integration of the agonist into the body of the user.
At the same time, it may be desired to prevent or reduce absorption
of any antagonist buccally, thereby allowing the antagonist to be
swallowed and destroyed in the stomach. Reducing the absorption of
an antagonist may be achieved via physical means, such as by
encapsulating the antagonist in a material that blocks absorption.
It is desired, however, to reduce the absorption of the antagonist
by chemical means, such as by controlling the local pH of the
dosage.
[0060] It has been found that by controlling the local pH of the
dosage form, the release and/or absorption of the actives therein
may be controlled. For example, in a dosage that includes an amount
of an agonist, the local pH may be controlled to a level that
maximizes its release and/or absorption into the oral cavity of the
user. In dosages incorporating an amount of an agonist and an
amount of an antagonist, the local pH may be controlled to a level
that maximizes the release and/or absorption of the agonist while
simultaneously minimizing the release and/or absorption of the
antagonist.
[0061] The dosage form preferably includes a combination of a
partial agonist and an antagonist, while the dosage has a
controlled pH. In one embodiment, the partial agonist may include
buprenorphine or a pharmaceutically acceptable salt thereof, while
the antagonist includes naloxone or a therapeutically acceptable
salt thereof. It should be understood that the present invention is
not limited to the use of buprenorphine and naloxone, and any
agonist (or partial agonist) and any antagonist may be incorporated
into the present invention for use in treatment of drug addiction.
The agonist and optional antagonist should be selected from those
agonists and antagonists that are useful in treating the particular
narcotic dependence being treated.
[0062] As discussed above, the local pH of the dosage is preferably
controlled to provide the desired release and/or absorption of the
agonist and antagonist. Buprenorphine is known to have a pKa of
about 8.42, while naloxone has a pKa of about 7.94. According to pH
partition theory, one would expect that saliva (which has a pH of
about 6.5) would maximize the absorption of both actives. However,
it has been surprisingly discovered by the Applicants that by
buffering the dosage to a particular pH level, the optimum levels
of absorption of the agonist and antagonist may be achieved.
Desirably, the local pH of a composition including an agonist and
an antagonist is between about 2 to about 4, and most desirably is
from 3 to 4. At this local pH level, the optimum absorption of the
agonist and the antagonist is achieved. As will be described in
more detail in the Examples below, controlling the local pH of the
film compositions of the present invention provides a system in
which the desired release and/or absorption of the components is
bioequivalent to that of a similar Suboxone.RTM. tablet.
[0063] In one embodiment, the dosage form is a self-supporting
film. In this embodiment, the film dosage includes a polymer
carrier matrix, a therapeutically effective amount of
buprenorphine, an agonist. The buffer is preferably capable of
providing a local pH of the composition within a range that
provides the desired level of absorption of the buprenorphine. The
resulting dosage is a film composition that allows for a rapid and
effective release of buprenorphine into the oral cavity of the
user. At the same time, the film composition preferably has a
sufficient adhesion profile, such that the film cannot easily be
removed from the oral cavity of the user once it has been placed
into the cavity. Full release of the buprenorphine preferably takes
place within less than about thirty minutes, and preferably remains
in the oral cavity for at least 1 minute.
[0064] As explained above, while providing a pharmaceutically
acceptable level of an agonist is helpful in treating those with
narcotic addiction, it may be desirable to provide the
buprenorphine in combination with naloxone (an antagonist) so as to
reduce the effect of the agonist and therefore aid in reducing
dependency of the narcotic. Therefore, it may be desirable to
combine the opioid agonist (or partial agonist) in the film
composition with an opioid antagonist or a pharmaceutically
acceptable salt thereof. The actives may be dispersed throughout
the dosage separately or they may be combined together and
dispersed into the dosage. Most desirably the antagonist includes
naloxone, but any suitable basic antagonist may be selected as
desired. The antagonist may optionally be water-soluble, so as to
render separation of the antagonist and agonist difficult, thereby
lessening the potential for abuse of the agonist.
[0065] As with a film including an agonist, the film including an
agonist and an antagonist is desirably pH-controlled through the
inclusion of a buffer. In such combination films, it has been
discovered that the local pH of the film composition should
preferably be in the range of about 2 to about 4, and more
preferably about 3 to about 4 so as to provide a bioequivalent
product as the commercially-available Suboxone.RTM. tablet. Most
preferably the local pH of the film composition is about 3.5. At
this local pH level, absorption of the buprenorphine is optimized
while the absorption of the naloxone is inhibited.
[0066] The film may contain any desired level of self-supporting
film forming polymer, such that a self-supporting film composition
is provided. In one embodiment, the film composition contains a
film forming polymer in an amount of at least 25% by weight of the
composition. The film forming polymer may alternatively be present
in an amount of at least 50% by weight of the composition. As
explained above, any film forming polymers that impart the desired
mucoadhesion and rate of film dissolution may be used as
desired.
[0067] Any desired level of agonist and optional antagonist may be
included in the dosage, so as to provide the desired effect. In one
particular embodiment, the film composition includes about 2 mg to
about 16 mg of agonist per dosage. More desirably, the film
composition includes about 4 mg to about 12 mg of agonist per
dosage. If desired, the film composition may include about 0.5 mg
to about 5 mg of antagonist per dosage. More desirably, the film
composition includes about 1 mg to about 3 mg of antagonist per
dosage. If an antagonist is incorporated into the film, the film
composition may include the antagonist in a ratio of about 6:1-2:1
agonist to antagonist. Most desirably, the film composition
contains about 4:1 agonist to antagonist per dosage. For example,
in one embodiment, the dosage includes an agonist in an amount of
about 12 mg, and includes an antagonist in an amount of about 3
mg.
[0068] The film compositions further desirably contains a buffer so
as to control the local pH of the film composition. Any desired
level of buffer may be incorporated into the film composition so as
to provide the desired local pH level. The buffer is preferably
provided in an amount sufficient to control the release from the
film and/or the absorption into the body of the agonist and the
optional antagonist. In a desired embodiment, the film composition
includes buffer in a ratio of buffer to agonist in an amount of
from about 2:1 to about 1:5 (buffer:agonist). The buffer may
alternatively be provided in a 1:1 ratio of buffer to agonist. As
stated above, the film composition preferably has a local pH of
about 2 to about 4, and most preferably has a local pH of about
3.5. Any buffer system may be used as desired. In some embodiments,
the buffer may include sodium citrate, citric acid, and
combinations thereof.
[0069] In this embodiment, the resulting film composition includes
a polymer matrix, an agonist, and an optional antagonist, while the
film composition has a controlled local pH to the level desired.
The buffer is preferably present in an amount to provide a
therapeutically adequate absorption of the agonist, while
simultaneously limiting the absorption of the antagonist.
Controlling of the local pH allows for the desired release and/or
absorption of the components, and thus provides a more useful and
effective dosage.
[0070] The film dosage composition may include a polymer carrier
matrix, a therapeutically effective amount of agonist, a
therapeutically effective amount of antagonist, and a buffering
system. The buffering system may include a buffer in addition to a
solvent. The buffering system desirably includes a sufficient level
of buffer so as to provide a desired local pH level of the film
dosage composition.
[0071] In addition to a desired local pH level, the buffer
preferably has a buffer capacity sufficient to maintain the
ionization of the optional antagonist during the time that the
composition is in the oral cavity of a user. Maintaining the
ionization of the antagonist serves to limit the absorption of the
antagonist, and thus provide the desired control of the antagonist.
While the ionization of the antagonist is limited, the ionization
of the agonist may not be so limited. As such, the resulting dosage
form provides absorption of the agonist to the user, while
sufficiently reducing and/or preventing absorption of the
antagonist. By keeping the antagonist ionized and the local pH at
the optimum pH, the antagonist has limited if any absorption, but
is still present should the product be abused or taken via a
different route of administration. However, when taken as
administered, the antagonist has little to no effect in blocking
the agonist.
[0072] The film dosage composition including an agonist may be
configured to provide an in vivo plasma profile having a mean
maximum plasma concentration (Cmax) in a desired range. It has been
discovered by the Applicants that controlling the Cmax of the film
composition allows one to control the absorption of the active
(such as an agonist) into the user. The resulting film composition
is more effective and suitable for delivery to a user.
[0073] As explained, the film dosage composition provides a
bioequivalent result to a commercially available Suboxone.RTM.
product. As will be explained more in the Examples below,
commercially available Suboxone.RTM. provides different absorption
levels depending on the amount of buprenorphine and naloxone
administered. The present invention desirably provides a film
product providing bioequivalent release as that of the
Suboxone.RTM. product. As with the Suboxone.RTM. product, the
buprenorphine may be present in an amount of from about 2 mg to
about 16 mg per dosage, or, if desired about 4 mg to about 12 mg
per dosage. Additionally, the naloxone may be present in any
desired amount, preferably at about 25% the level of buprenorphine.
For example, an inventive film product may have 2 mg buprenorphine
and 0.5 mg naloxone, 4 mg buprenorphine and 1 mg naloxone, 8 mg
buprenorphine and 2 mg naloxone, 12 mg buprenorphine and 3 mg
naloxone, 16 mg buprenorphine and 4 mg naloxone, or any similar
amounts.
[0074] It has further been discovered that, by controlling the mean
area under the curve (AUC) value of the film composition, a more
effective dosage form may be provided. As is described in more
detail in the Examples below, the inventive film composition
preferably provides an AUC value so as to provide a bioequivalent
result as that provided by the commercially available Suboxone.RTM.
tablet. In one embodiment, the film composition may include a mean
AUCinf value of about 6.8 hr.ng/ml or greater. Alternatively, the
film composition may include a mean AUCinf value of from about 6.8
hr.ng/ml to about 66 hr.ng/ml.
[0075] As explained above, the film compositions may include
naloxone, an antagonist. When the film composition includes a
combination of agonist and antagonist, the film composition may be
configured to provide a particular Cmax and/or AUCinf for the
antagonist. For example, when a buprenorphine agonist and a
naloxone antagonist are incorporated into the film composition, the
naloxone may be configured to provide a Cmax of less than about 400
pg/ml, less than about 318 pg/ml, less than about 235 pg/ml, less
than about 92 pg/ml or less than about 64 pg/ml. In such films, the
naloxone may provide a mean AUCinf value of less than about 1030
hr.ng/ml.
[0076] In formulations which include an agonist in combination with
an antagonist, the film composition may be prepared to provide a
desired Cmax and/or AUCinf value for each of the agonist and
antagonist. In one embodiment, the film composition provides an in
vivo plasma profile having a Cmax of less than about 6.4 ng/ml for
the agonist and an in vivo plasma profile having a Cmax of less
than about 400 pg/ml for the antagonist. In such embodiments, the
formulation may provide an AUCinf value of more than about 6.8
hr.ng/ml for the agonist. If desired, the formulation may provide
an AUCinf value of less than about 1030 hr.pg/ml for the
antagonist. Such compositions may include the agonist and the
antagonist in any desired amount, and in a preferred embodiment,
the composition includes about 2 mg to about 16 mg of the agonist
per dosage and about 0.5 mg to about 4 mg of the antagonist per
dosage.
[0077] The present invention provides a method of treating narcotic
dependence in a patient. In one embodiment, the patient is
dependent on opioid narcotics, but the patient may have a
dependence on non-opioid narcotics. Desirably, the patient is
treated by providing a dosage to the patient, which provides an
effective release of actives but simultaneously provides a suitable
adhesion so that the dosage cannot be easily removed. In one method
of treatment, an orally dissolvable film composition is provided to
a patient.
[0078] Depending on the particular narcotic that the patient
experiences dependence upon, the film composition may include one
or more particular active components. In one embodiment, the film
composition includes a polymer carrier matrix and a therapeutically
effective amount of an agonist. Desirably the agonist is a partial
agonist. For opioid dependency, the agonist may be an opioid
agonist, such as buprenorphine or a pharmaceutically acceptable
salt thereof. The film composition preferably includes a buffer in
an amount sufficient to control the local pH of the film
composition. Any buffer system may be used, including sodium
citrate, citric acid, and combinations thereof. In compositions
solely including an agonist, the local pH of the film composition
is desirably about 5 to about 6.5, and most desirably the local pH
is about 5.5. At this level, the absorption of the agonist is most
effective. To treat the dependency, the film composition is
administered to the patient, most desirably into the oral cavity of
the patient.
[0079] If desired, the composition may include a therapeutically
effective amount of an antagonist, to prevent abuse of the agonist.
A "therapeutically effective amount" of an antagonist is intended
to refer to an amount of the antagonist that may be useful in
diverting abuse of the agonist by a user. The antagonist may be any
desired antagonist, and in one embodiment includes naloxone or a
pharmaceutically acceptable salt thereof. The film composition is
preferably administered to a patient through the oral cavity of the
patient, but may be administered in any desired means. The orally
dissolvable film composition is then allowed to dissolve in the
oral cavity of the patient for a sufficient time so as to release
the active(s) therein. In some embodiments, the film composition
may remain in the oral cavity for at least 30 seconds, and in some
embodiments may remain in the oral cavity for at least 1 minute.
After the film composition is placed into the oral cavity of the
patient, the film preferably becomes sufficiently adhered so as to
render its removal difficult. After the film composition has been
administered to the patient, the active(s) are sufficiently
released from the composition and allowed to take effect on the
patient.
[0080] The film compositions of the present invention may be formed
via any desired process. Suitable processes are set forth in U.S.
Pat. Nos. 7,425,292 and 7,357,891, the entire contents of which are
incorporated by reference herein. In one embodiment, the film
dosage composition is formed by first preparing a wet composition,
the wet composition including a polymeric carrier matrix, a
therapeutically effective amount of an agonist, and a buffer in an
amount sufficient to control the local pH of the composition to a
desired level. The wet composition is cast into a film and then
sufficiently dried to form a self-supporting film composition. The
wet composition may be cast into individual dosages, or it may be
cast into a sheet, where the sheet is then cut into individual
dosages. The agonist may be a partial agonist. If desired, the wet
composition may include a therapeutically effective amount of an
antagonist.
[0081] The agonist and the optional antagonist are preferably
selected to treat a particular narcotic dependency. For opioid
dependency, for example, the agonist may include buprenorphine or a
pharmaceutically acceptable salt thereof, while the antagonist may
include naloxone or a pharmaceutically acceptable salt thereof. The
local pH of the film composition is desirably maintained at about 2
to about 4.
EXAMPLES
Example 1
Composition of Buprenorphine/Naloxone Films at Various
Strengths
[0082] Film strips including a combination of buprenorphine and
naloxone were prepared. Four different strength film compositions
were prepared, which include a ratio of buprenorphine to naloxone
of 16/4, 12/3, 8/2, and 2/0.5. The compositions are summarized in
Table 1 below.
TABLE-US-00001 TABLE 1 Various Compositions of Film Dosages
Buprenorphine/Naloxone Films Unit Formula (mg per film strip)
Buprenorphine/Naloxone Ratios Components 16/4 12/3 8/2 2/0.5 Active
Components Buprenorphine HCl 17.28 12.96 8.64 2.16 Naloxone HCl
Dihydrate 4.88 3.66 2.44 0.61 Inactive Components Polyethylene
Oxide, NF 27.09 20.32 13.55 -- (MW 200,000) Polyethylene Oxide, NF
12.04 9.03 6.02 19.06 (MW 100,000) Polyethylene Oxide, NF 4.82 3.62
2.41 2.05 (MW 900,000) Maltitol, NF 12.04 9.03 6.02 5.87 Flavor 6.0
4.5 3.0 2.4 Citric Acid, USP 5.92 4.44 2.96 2.96 HPMC 4.22 3.16
2.11 2.34 Ace-K 3.0 2.25 1.5 1.2 Sodium Citrate, anhydrous 2.68
2.01 1.34 1.34 Colorant 0.03 0.02 0.01 0.01 Total (mg) 100 75 50
40
Example 2
Absorption Studies for Suboxone.RTM. Products
[0083] Various film and tablet products were prepared and tested
for absorption data, including Cmax and AUC absorption levels. The
products tested included Suboxone.RTM. tablets made with either 2
mg or 16 mg buprenorphine as well as either 0.5 mg or 4.0 mg
naloxone. For 16 mg buprenorphine tablets, two 8 mg buprenorphine
tablets were combined together to provide the level of components
of a 16 mg buprenorphine tablet. In instances where a 12 mg
buprenorphine tablet was evaluated, this dosage was obtained by
combining one 8 mg buprenorphine tablet and two 2 mg buprenorphine
tablets. These products were tested for absorption levels, with the
amounts listed in Table 2 below.
TABLE-US-00002 TABLE 2 Absorption Data for Suboxone .RTM. products
Sample C max AUC Buprenorphine (2 mg) Suboxone .RTM. 0.780 ng/ml
6.789 hr * ng/ml Tablet Naloxone (0.5 mg) Suboxone .RTM. 51.30
pg/ml 128.60 hr * pg/ml Tablet Buprenorphine (16 mg) Suboxone .RTM.
4.51 ng/ml 44.99 hr * ng/ml Tablet Naloxone (4 mg) Suboxone .RTM.
Tablet 259.00 pg/ml 649.60 hr * pg/ml
[0084] Using the data from Table 2, absorption data for the
Suboxone.RTM. tablets for other levels of buprenorphine and
naloxone are set forth in Table 2A below.
TABLE-US-00003 TABLE 2A Extrapolated Absorption Data for Suboxone
.RTM. products Sample C max AUC Buprenorphine (4 mg) Suboxone .RTM.
1.35 ng/ml 12.25 hr * ng/ml Tablet Naloxone (1 mg) Suboxone .RTM.
Tablet 80.97 pg/ml 203 hr * pg/ml Buprenorphine (8 mg) Suboxone
.RTM. 2.29 ng/ml 23.17 hr * ng/ml Tablet Naloxone (2 mg) Suboxone
.RTM. Tablet 140.31 pg/ml 351.8 hr * pg/ml Buprenorphine (12 mg)
Suboxone .RTM. 3.23 ng/ml 34.08 hr * ng/ml Tablet Naloxone (3 mg)
Suboxone .RTM. Tablet 199.7 pg/ml 500.6 hr * pg/ml
Example 3
Evaluation of Bioequivalence of Suboxone.RTM. Tablets
[0085] Using the data generated for Suboxone.RTM. tablets in Table
2 above, acceptable bioequivalence ranges are generated to provide
an equivalent treatment level as the Suboxone.RTM. tablet. As
currently understood, a product provides a bioequivalent effect if
it provides absorption levels between about 80% to about 125% of
the Suboxone.RTM. tablet. Absorption in this range is considered to
be bioequivalent.
TABLE-US-00004 TABLE 3 Acceptable Bioequivalence Ranges for
Suboxone .RTM. Tablets (80 to 125%) Description of Sample C max AUC
Buprenorphine 0.624 to 0.975 ng/ml 5.431 to 8.486 hr * ng/ml 2 mg
Naloxone 41.04 to 64.13 pg/ml 102.88 to 160.75 hr * pg/ml 0.5 mg
Buprenorphine 3.608 to 5.638 ng/ml 35.992 to 56.238 hr * ng/ml 16
mg Naloxone 4 mg 207.20 to 323.75 pg/ml 519.68 to 812.00 hr *
pg/ml
[0086] Thus, to be considered bioequivalent to the Suboxone.RTM.
tablet, the Cmax of buprenorphine is between about 0.624 and 5.638,
and the AUC of buprenorphine is between about 5.431 to about
56.238. Similarly, to be considered bioequivalent to the
Suboxone.RTM. tablet, the Cmax of naloxone is between about 41.04
to about 323.75, and the AUC of naloxone is between about 102.88 to
about 812.00.
Example 4
Absorption Studies for Film Products at pH 3.5
[0087] Various film products were prepared and tested for
absorption data, including Cmax and AUC absorption levels. The
products tested included inventive film strips, the film strips
having either 2 mg or 16 mg buprenorphine as well as either 0.5 mg
or 4.0 mg naloxone. These products were tested for absorption
levels, with the amounts listed in Table 4 below.
TABLE-US-00005 TABLE 4 Absorption Data for inventive film products
at pH 3.5 Sample C max AUC Buprenorphine (2 mg) Sublingual 0.947
ng/ml 7.82 hr * ng/ml Film Naloxone (0.5 mg) Sublingual Film 51.10
pg/ml 128.60 hr * pg/ml Buprenorphine (16 mg) Sublingual 5.47 ng/ml
55.30 hr * ng/ml Film Naloxone (4 mg) Sublingual Film 324.00 pg/ml
873.60 hr * pg/ml
[0088] As can be seen, in this experiment, the values for
buprenorphine absorbance were squarely in the bioequivalence range
evaluated above. The inventive films were therefore determined to
have provided a bioequivalent absorption of buprenorphine at a
local pH of 3.5 as the commercially available Suboxone.RTM. tablet.
The values for absorption of naloxone were very close to the
bioequivalent range of Suboxone.RTM.. The slightly higher
absorption of Naloxone was not due to the local pH but rather to
the amount of buffer (buffer capacity as discussed in the
application). This is confirmed by the fact that the lower 2/0.5 mg
dose is in range for the Naloxone and this is due to the higher
buffer capacity for the 2/0.5 dose as pointed out in the buffer
capacity chart.
Example 5
Preparation of Films for In Vivo Study
[0089] Film dosages were prepared for use in an in vivo study to
determine the bioavailability of buprenorphine/naloxone tablets and
film formulations. Specifically, the films were tested to determine
whether the film provides a bioequivalent effect to that of a
tablet formulation.
[0090] Three film formulations including 8 mg buprenorphine and 2
mg naloxone were prepared, each being buffered to a different pH.
The first film did not include any buffer, providing a local pH of
about 6.5. The second was buffered to a local pH level of about
3-3.5. The third was buffered to a local pH value of about 5-5.5.
The formulations are set forth in Table 5 below.
TABLE-US-00006 TABLE 5 Formulations of Test Films at Various pH
Levels Test Test Test formulation 1 formulation 2 formulation 3 8
mg/2 mg 8 mg/2 mg 8 mg/2 mg pH = 6.5 pH = 3-3.5 pH = 5-5.5
Component % w/w Mg/film % w/w Mg/film % w/w Mg/film Buprenorphine
21.61 8.64 17.28 8.64 17.28 8.64 HCl Naloxone HCl 6.10 2.44 4.88
2.44 4.88 2.44 Dihydrate Polymer 5.05 2.02 4.82 2.41 4.82 2.41
Polymer 28.48 11.39 27.09 13.55 27.09 13.55 Polymer 12.65 5.06
12.04 6.02 12.04 6.02 Polymer 4.43 1.77 4.22 2.11 4.22 2.11
Sweetener 12.65 5.06 12.04 6.02 12.04 6.02 Sweetener 3 1.2 3 1.5 3
1.5 Flavor 6 2.4 6 3 6 3 Citric acid 0 0 5.92 2.96 2.51 1.26 Sodium
citrate 0 0 2.68 1.34 6.08 3.04 FD&C yellow 0.025 0.01 0.03
0.02 0.03 0.02 #6 Total 100 40 100 50 100 50
Example 6
Analysis of In Vivo Absorption of Film Having a pH of 6.5
[0091] The film dosage composition of film having a local pH of 6.5
was analyzed. Specifically, Test Formulation 1, as prepared in
Example 5 was analyzed in vivo to determine the absorption of
buprenorphine and of naloxone. The comparative film was compared to
the absorption of buprenorphine and of naloxone provided by a one
dose tablet (Suboxone.RTM.). The test film was compared to
determine whether it provided a bioequivalent effect as the tablet
product.
[0092] The results for Test Formulation 1, which had a local pH of
about 6.5, as compared to the one dose tablet, are set forth in
Tables 6 and 7 below.
TABLE-US-00007 TABLE 6 Buprenorphine In Vivo Absorption Data for
Test Formulation 1 Test Formulation 1 Suboxone .RTM. sublingual (pH
= 6.5) Parameter n Mean SD CV % n Mean SD CV % T.sub.max (hr) 15
1.60 0.47 29.41 15 1.50 0.62 41.23 C.sub.max 15 2.27 0.562 24.77 15
2.60 0.872 33.53 (ng/mL) AUC.sub.last 15 27.08 10.40 38.41 15 31.00
12.93 41.72 (hr * ng/ mL) AUC.sub.inf 15 29.58 11.15 37.68 15 33.37
13.88 41.61 (hr * ng/ mL) T.sub.1/2 (hr) 15 44.76 20.86 46.60 15
40.73 14.93 36.66
TABLE-US-00008 TABLE 7 Naloxone In Vivo Absorption Data for Test
Formulation 1 Suboxone .RTM. sublingual Test Formulation 1 (pH =
6.5) Parameter n Mean SD CV % n Mean SD CV % T.sub.max (hr) 15 0.90
0.23 25.32 15 0.68 0.18 25.75 C.sub.max (pg/mL) 15 94.6 39.1 41.33
15 410 122 29.75 AUC.sub.last 15 297.1 120.7 40.62 15 914.8 158.1
17.29 (hr * pg/mL) AUC.sub.inf (hr * pg/mL) 15 306.1 122.6 40.06 15
924.2 158.8 17.18 T.sub.1/2 (hr) 15 6.62 2.60 39.26 15 6.86 2.08
30.27
[0093] As can be seen, the in vivo data indicates that
buprenorphine is absorbed very well from the film formulation at a
local pH of 6.5, and matched closely the absorption seen in the
Suboxone.RTM. one dose tablet. However, the absorption was also
maximized for the naloxone, which was undesirable. It was
determined that a film having a combination of buprenorphine and
naloxone and a local pH of 6.5 did not provide a bioequivalent
effect as the Suboxone.RTM. tablet for both buprenorphine and
naloxone.
Example 7
Analysis of In Vivo Absorption of Film Having a pH of 5-5.5
[0094] Having determined the absorption of buprenorphine and
naloxone in film having a local pH of 6.5, a film dosage
composition of film having a local pH of 5-5.5 was analyzed.
Specifically, Test Formulation 3, as prepared in Example 5 was
analyzed in vivo to determine the absorption of buprenorphine and
of naloxone. The comparative films were compared to the absorption
of buprenorphine and of naloxone provided by the Suboxone.RTM. one
dose tablet. The test film was compared to determine whether it
provided a bioequivalent effect as the Suboxone.RTM. tablet.
[0095] The results for Test Formulation 3, which had a local pH of
about 5-5.5, as compared to the Suboxone.RTM. tablet, are set forth
in Tables 8 and 9 below.
TABLE-US-00009 TABLE 8 Buprenorphine In Vivo Absorption Data for
Test Formulation 3 Test Formulation 3 Suboxone .RTM. sublingual (pH
= 5-5.5) Parameter n Mean SD CV % n Mean SD CV % T.sub.max (hr) 15
1.60 0.47 29.41 14 1.50 0.43 28.50 C.sub.max 15 2.27 0.562 24.77 14
3.47 1.57 45.40 (ng/mL) AUC.sub.last 15 27.08 10.40 38.41 14 33.25
16.01 48.16 (hr * ng/mL) AUC.sub.inf 15 29.58 11.15 37.68 13 38.34
15.38 40.13 (hr * ng/mL) T.sub.1/2 (hr) 15 44.76 20.86 46.60 13
41.71 17.70 42.42
TABLE-US-00010 TABLE 9 Naloxone In Vivo Absorption Data for Test
Formulation 3 Suboxone .RTM. sublingual Test Formulation 3 (pH =
5-5.5) Parameter n Mean SD CV % n Mean SD CV % T.sub.max (hr) 15
0.90 0.23 25.32 14 0.98 0.62 63.51 C.sub.max (pg/mL) 15 94.6 39.1
41.33 14 173 84.5 48.79 AUC.sub.last 15 297.1 120.7 40.62 14 455.2
195.5 42.94 (hr * pg/mL) AUC.sub.inf (hr * pg/mL) 15 306.1 122.6
40.06 13 474.4 203.1 42.81 T.sub.1/2 (hr) 15 6.62 2.60 39.26 13
9.45 6.90 73.00
[0096] As can be seen, the in vivo data indicated that the
absorption of buprenorphine increased as the local pH level
decreased. It appeared that by decreasing the local pH from 6.5 to
5.5, the absorption of buprenorphine was being moved to a level
further away from that of the one dose tablet. In addition, the
naloxone values did not provide a bioequivalent result as the one
dose tablet. Thus, it was determined that the film having a local
pH of 5.5 did not provide a bioequivalent result as that of the
Suboxone.RTM. tablet for both buprenorphine and naloxone.
[0097] It was noted that by reducing the local pH of the film to a
level of 5.5, there would be provided an increased level of
absorption of buprenorphine. Thus, it may be desirable to buffer a
film composition incorporating buprenorphine itself to a level of
about 5.5 to provide an increased absorption.
Example 8
Analysis of In Vivo Absorption of Film Having a pH of 3-3.5
[0098] Having determined the absorption of buprenorphine and
naloxone in films having a local pH of 6.5 and 5.5, a film dosage
composition of film having a local pH of about 3-3.5 was analyzed.
It was assumed that the absorption of buprenorphine would continue
to be increased as it had demonstrated at a local pH of 5.5. Thus,
it was assumed that at a local pH of 3.5, the film would not be
bioequivalent to that of the tablet.
[0099] Specifically, Test Formulation 2, as prepared in Example 5,
was analyzed in vivo to determine the absorption of buprenorphine
and of naloxone. The comparative films were compared to the
absorption of buprenorphine and of naloxone provided by the
Suboxone.RTM. one dose tablet. The test film was compared to
determine whether it provided a bioequivalent effect as the tablet
product.
[0100] The results for Test Formulation 2, which had a local pH of
about 3-3.5, as compared to the Suboxone.RTM. tablet, are set forth
in Tables 10 and 11 below.
TABLE-US-00011 TABLE 10 Buprenorphine In Vivo Absorption Data for
Test Formulation 2 Test Formulation 2 Suboxone .RTM. sublingual (pH
= 3-3.5) Parameter n Mean SD CV % n Mean SD CV % T.sub.max (hr) 15
1.60 0.47 29.41 14 1.68 0.58 34.68 C.sub.max 15 2.27 0.562 24.77 14
2.68 0.910 33.99 (ng/mL) AUC.sub.last 15 27.08 10.40 38.41 14 29.73
12.05 40.54 (hr * ng/ mL) AUC.sub.inf 15 29.58 11.15 37.68 14 31.45
12.98 41.26 (hr * ng/ mL) T.sub.1/2 (hr) 15 44.76 20.86 46.60 14
30.03 13.95 46.46
TABLE-US-00012 TABLE 11 Naloxone In Vivo Absorption Data for Test
Formulation 2 Suboxone .RTM. sublingual Test Formulation 2 (pH =
3-3.5) Parameter n Mean SD CV % n Mean SD CV % T.sub.max (hr) 15
0.90 0.23 25.32 14 0.84 0.19 22.19 C.sub.max (pg/mL) 15 94.6 39.1
41.33 14 130 72.9 56.04 AUC.sub.last 15 297.1 120.7 40.62 14 362.2
155.9 43.03 (hr * pg/mL) AUC.sub.inf (hr * pg/mL) 15 306.1 122.6
40.06 12 350.4 142.3 40.61 T.sub.1/2 (hr) 15 6.62 2.60 39.26 12
8.07 4.75 58.84
[0101] As can be seen, the in vivo data indicated that the
absorption of buprenorphine was substantially bioequivalent to that
of the one dose tablet when the film composition local pH was
lowered to about 3-3.5. This result was surprising as it did not
appear to follow the pH partition theory. Further, at a local pH of
about 3-3.5, it was seen that the absorption of naloxone was
substantially bioequivalent to that of the one dose tablet.
[0102] Thus, it was determined that the film product including
buprenorphine and naloxone at a local pH of 3-3.5 was substantially
bioequivalent to that of the Suboxone.RTM. one dose tablet.
Example 9
Normalized Values for Naloxone in Films and Tablets
[0103] Various film compositions including buprenorphine and
naloxone in 8/2 mg and 2/0.5 mg dosages, and having different local
pH values from 6.5 to 3.5, were prepared and analyzed. The data was
normalized and compared to the one dose tablet. The results are set
forth in Table 12 below.
TABLE-US-00013 TABLE 12 Normalized Values for Naloxone Film
Compared to Tablet Ratio Citric Dose (mg) Mg Acid Buprenorphine/
AUC Citric (mg)/Naloxone pH Naloxone (Normalized) Cmax Acid (mg)
6.5 8/2 3.02 4.33 1.34 0.67 5.5 8/2 1.55 1.83 1.34 0.67 3.5 8/2
1.14 1.37 1.34 0.67 3.5 2/0.5 0.98 0.90 1.34 2.68 5.5 2/0.5 1.41
1.41 1.34 2.68
[0104] The data indicates that not only is the local pH of
significant importance, but the amount of buffer present in the
formula is also important. The improvement from the 8/2 dose to the
2/0.5 dose (at a local pH of 3.5) demonstrates this importance. The
8/2 dose has a ratio of buffer/naloxone of 0.67, and this dose
provided borderline acceptable bioequivalent results. In contrast,
the 2/0.5 dose has a ratio of buffer/naloxone of 2.68, and provides
a more bioequivalent absorption value than the 8/2 dose.
[0105] In fact, the data shows that the 2/0.5 dose at a local pH of
3.5 had an even lower buccal absorption than the one dose tablet,
as seen from the normalized values for the AUC and Cmax. This
demonstrates that even less absorption of the naloxone occurs for
the film formulation at a local pH of 3.5 than the tablet
formulation. Given the goal of reducing the absorption of naloxone,
it appears that the film product buffered at a local pH of 3.5 with
a buffer ratio of buffer/Naloxone of 2.68 provides even better
results than the Suboxone.RTM. tablet formulation.
* * * * *